Läubli H - Search Results

1

Tools to study and target the Siglec-sialic acid axis in cancer.

Läubli H, Kawanishi K, George Vazhappilly C, Matar R, Merheb M, Sarwar Siddiqui S. Läubli H, et al. FEBS J. 2021 Nov;288(21):6206-6225. doi: 10.1111/febs.15647. Epub 2020 Dec 21. FEBS J. 2021. PMID: 33251699 Free article. Review.

2

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, Corral de la Fuente E, Hess D, König D, Sanchez Perez V, Bucher C, Jethwa S, Garralda E. Joerger M, et al. Among authors: laubli h. J Immunother Cancer. 2023 Nov 21;11(11):e007784. doi: 10.1136/jitc-2023-007784. J Immunother Cancer. 2023. PMID: 38243906 Free PMC article. Clinical Trial.

3

Sialic acids in cancer biology and immunity.

Pearce OM, Läubli H. Pearce OM, et al. Among authors: laubli h. Glycobiology. 2016 Feb;26(2):111-28. doi: 10.1093/glycob/cwv097. Epub 2015 Oct 30. Glycobiology. 2016. PMID: 26518624 Review.

4

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.

Adams OJ, Stanczak MA, von Gunten S, Läubli H. Adams OJ, et al. Among authors: laubli h. Glycobiology. 2018 Sep 1;28(9):640-647. doi: 10.1093/glycob/cwx108. Glycobiology. 2018. PMID: 29309569 Free article. Review.

5

Siglec-9 Regulates an Effector Memory CD8⁺ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Seyed Jafari SM, Zippelius A, Baerlocher GM, Läubli H, Hunger RE, Romero P, Simon HU, von Gunten S. Haas Q, et al. Among authors: laubli h. Cancer Immunol Res. 2019 May;7(5):707-718. doi: 10.1158/2326-6066.CIR-18-0505. Epub 2019 Apr 15. Cancer Immunol Res. 2019. PMID: 30988027

6

Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.

Läubli H, Varki A. Läubli H, et al. Cell Mol Life Sci. 2020 Feb;77(4):593-605. doi: 10.1007/s00018-019-03288-x. Epub 2019 Sep 4. Cell Mol Life Sci. 2020. PMID: 31485715 Free PMC article. Review.

7

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.

Bärenwaldt A, Läubli H. Bärenwaldt A, et al. Among authors: laubli h. Expert Opin Ther Targets. 2019 Oct;23(10):839-853. doi: 10.1080/14728222.2019.1667977. Epub 2019 Sep 23. Expert Opin Ther Targets. 2019. PMID: 31524529 Review.

8

Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.

Läubli H, Nalle SC, Maslyar D. Läubli H, et al. Cancer Immunol Res. 2022 Dec 2;10(12):1423-1432. doi: 10.1158/2326-6066.CIR-22-0366. Cancer Immunol Res. 2022. PMID: 36264237 Free PMC article. Review.

9

Unraveling the impact of a glyco-immune checkpoint in bone metastasis.

Läubli H. Läubli H. Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2400499121. doi: 10.1073/pnas.2400499121. Epub 2024 Feb 20. Proc Natl Acad Sci U S A. 2024. PMID: 38377217 No abstract available.

10

Regulation of sialic acid metabolism in cancer.

Filipsky F, Läubli H. Filipsky F, et al. Among authors: laubli h. Carbohydr Res. 2024 May;539:109123. doi: 10.1016/j.carres.2024.109123. Epub 2024 Apr 22. Carbohydr Res. 2024. PMID: 38669826 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

100 results

Search Page